No Detail Found!

Prognostic factors a ecting day+100 survival in patients undergoing allogeneic haematopoietic stem cell transplantation for acute leukaemia - a single centre experience

Author(s)
Awais Siddiq Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, CMH Medical Complex,Rawalpindi,Pakistan
Mehreen Ali Khan Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, CMH Medical Complex,Rawalpindi,Pakistan
Jehanzeb Ur Rehman Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, CMH Medical Complex,Rawalpindi,Pakistan
Yasir Abbas Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, CMH Medical Complex,Rawalpindi,Pakistan
Hashim Khan Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, CMH Medical Complex,Rawalpindi,Pakistan
Uzma Rahim Department of Clinical Haematology, Armed Forces Bone Marrow Transplant Centre, CMH Medical Complex,Rawalpindi,Pakistan
Abstract
Objective: To determine the factors a ecting the rst 100 days of survival in acute leukaemia patients undergoing allogeneic haematopoietic stem cell transplantation (Allo-HSCT). Study Design: Descriptive study. Place and Duration of the Study: Bone Marrow Transplant Centre, Rawalpindi, Pakistan, from March 2016 to February 2022. Methodology: Patients with acute myeloid leukaemia (AML) or acute lymphoblastic leukaemia (ALL) in complete remission (CR) undergoing Allo-HSCT were included. Data were collected on patient demographics, diagnosis, remission status, pre-transplant analysis, donor compatibility, conditioning regimen, GVHD prophylaxis, engraftment times, post-transplant complications, mortality causes, and overall survival (OS) at 100 days. Results: Among 101 transplant recipients (mean age of 24 ± 11.05 years; n = 76 males, n = 25 females), 41 had AML and 60 had ALL. Ninety patients underwent matched sibling donor (MSD)-HSCT, while 11 had haplo-identical sibling-HSCT. Patients d13 years had higher survival rates than older patients (94.4%vs. 67.5%, p = 0.03). High pre-transplant serum ferritin levels (>2500 mg/dl) predicted lower OS (48.9% vs. 100% in ferritin <1000 mg/dl, p <0.01). AML patients had a survival advantage over ALL patients (82.9% vs. 65%, p = 0.05). Early neutrophil engraftment within 14 days correlated with better survival (96.4%vs. 54.3%, p <0.01). Lastly, severe mucositis also adversely a ected survival (60% in Grade III vs. 9.5% in Grade IV, p <0.01). Conclusion: Identifying modi able factors can improve long-term support and follow-up, enhancing the patient outcomes in underdeveloped nations.
Publication Details
Page(s) 1287-1293
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 11, Year: 2024

Request the full text from PASTIC

Keywords
Pakistan, Acute leukaemia, Haematopoietic stem cell transplant, Day + 100 survival
0

Citations

0

Downloads

48

Views